Major Tax Update: Big Wins for U.S. Companies Investing in Innovation
At Hito, we work with companies where innovation isn’t just a catchy buzzword. We know how critical every dollar of liquidity is when you’re investing heavily in research and development.
Since 2022, changes to Section 174 of the Internal Revenue Code have made that investment more expensive in the short term. But that may be about to change.
The new Senate proposal could restore immediate deductions for domestic R&D and potentially allow small businesses to retroactively unlock major tax savings. Here’s what’s happening, what it means for your company, and how to prepare now.
Why Section 174 Amortization Has Been a Challenge
Before 2022, companies could deduct their qualified R&D expenses immediately under Section 174 of the Internal Revenue Code. That flexibility was a major benefit for early-stage and high-growth companies relying on strong year-one deductions and liquidity.
When the Tax Cuts and Jobs Act (TCJA) changes took effect, the impact was immediate:
- Smaller year-one tax deductions
- Tighter cash flows and reduced liquidity
- More complex planning around R&D tax credits and deductions
These effects have significantly reduced the near-term value of the Section 41 R&D tax credit, since it’s tied to current-year eligible expenses. With expenses amortized, the credit value drops.
What’s in the New Senate Proposal (Section 70302 / 174A)?
The Senate Finance Committee’s proposed legislation, released June 16, 2025, offers major relief and a strategic opportunity.
Full Expensing Returns (Starting 2025)
- Domestic R&D costs can be fully deducted in the year incurred (for tax years beginning after December 31, 2024).
- An optional 60-month amortization is available by election.
Software Development Included
- Development costs for software now qualify as domestic R&D under Section 174A.
Foreign R&D Still Amortized
- Costs for foreign research will remain subject to 15-year amortization.
Retroactive Relief for Small Businesses
Here’s where things get exciting for eligible small businesses: the Senate bill includes a transition rule allowing retroactive application of the new rules back to 2022 by filing amended returns. Eligible small businesses are defined as those whose average annual gross receipts for the prior three tax years do not exceed $31 million, determined by applying the aggregation rule where applicable under
Section 448(c)
What This Means:
- Immediate deduction of previously amortized R&D expenses
- Ability to file amended returns for 2022–2024
- Faster refunds and improved liquidity
Key Dates and Legislative Timeline
While the bill is advancing, it’s not the law yet. Here’s the current roadmap:
- Q2 2025: House reconciliation process completed
- Q3 2025: Senate floor vote Passed
- Q3 2025 Presidential signature and implementation
- Effective Date: Applies to tax years beginning after December 31, 2024
ERC Update: Deadline Has Passed, Audits Extended
While Section 174 may bring new relief, the Employee Retention Credit (ERC) door is now firmly closed.
ERC Deadline Passed
- No new claims for Q3/Q4 2021 allowed after January 31, 2024
- Only previously filed claims may still be processed
Extended IRS Enforcement
- IRS now has 6 years (up from 3) to audit ERC-related issues
- For Q3 and Q4 2021, the audit window extends until April 15, 2027
What Should Businesses Do Now?
The legislation is now a law; your tax planning shouldn’t wait.
Here’s your action plan:
- Summarize Amortized R&D (2022–2024) Identify total expenses previously amortized. You may be able to reclaim these via amended returns.
- Model Refund Scenarios If you qualify as a small business, calculate potential refunds under the retroactive provisions.
- Update Your Tax Strategy & Forecasting
- Begin planning for 2025 and beyond:
- Will you elect immediate expensing or 60-month amortization?
- How will this impact your Section 41 R&D credits?
- What changes should you make to your forecasting model?
Final Thoughts: This Isn’t Just a Fix, It’s a Strategic Opportunity
The return of full expensing under Section 174A could be a financial lifeline for innovation-driven companies. It’s not just about reversing an accounting rule. It’s about reclaiming cash, enhancing credit value, and building a smarter tax strategy.
At Hito, we’re already modeling scenarios for clients across tech, biotech, life sciences, and manufacturing. If your business relies on R&D, now is the time to prepare, not after the ink dries in Congress.
🔍 Learn more: Research & Development Tax Credits Explained
📞 Ready to explore your options? Schedule a consultation with our team at Hito LLC and see how much you’re leaving on the table